Merck Operating Expenses 2010-2022 | MRK

Merck annual/quarterly operating expenses history and growth rate from 2010 to 2022. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • Merck operating expenses for the quarter ending June 30, 2022 were $9.526B, a 1.85% decline year-over-year.
  • Merck operating expenses for the twelve months ending June 30, 2022 were $37.806B, a 1.75% decline year-over-year.
  • Merck annual operating expenses for 2021 were $35.505B, a 1.29% decline from 2020.
  • Merck annual operating expenses for 2020 were $35.97B, a 15.31% increase from 2019.
  • Merck annual operating expenses for 2019 were $31.195B, a 6.5% decline from 2018.
Merck Annual Operating Expenses
(Millions of US $)
2021 $35,505
2020 $35,970
2019 $31,195
2018 $33,363
2017 $33,325
2016 $34,308
2015 $31,951
2014 $35,554
2013 $36,368
2012 $37,390
2011 $39,071
2010 $42,632
2009 $23,407
Merck Quarterly Operating Expenses
(Millions of US $)
2022-06-30 $9,526
2022-03-31 $10,279
2021-12-31 $9,770
2021-09-30 $8,231
2021-06-30 $9,706
2021-03-31 $7,798
2020-12-31 $12,555
2020-09-30 $8,422
2020-06-30 $6,917
2020-03-31 $8,076
2019-12-31 $5,702
2019-09-30 $9,783
2019-06-30 $8,302
2019-03-31 $7,408
2018-12-31 $8,146
2018-09-30 $8,130
2018-06-30 $8,199
2018-03-31 $8,888
2017-12-31 $8,397
2017-09-30 $10,179
2017-06-30 $7,398
2017-03-31 $7,351
2016-12-31 $11,106
2016-09-30 $7,466
2016-06-30 $8,187
2016-03-31 $7,549
2015-12-31 $8,263
2015-09-30 $7,733
2015-06-30 $8,048
2015-03-31 $7,907
2014-12-31 $8,956
2014-09-30 $8,857
2014-06-30 $9,530
2014-03-31 $8,211
2013-12-31 $9,423
2013-09-30 $8,567
2013-06-30 $9,525
2013-03-31 $8,853
2012-12-31 $9,773
2012-09-30 $9,118
2012-06-30 $9,526
2012-03-31 $8,973
2011-12-31 $10,299
2011-09-30 $9,646
2011-06-30 $9,745
2011-03-31 $9,381
2010-12-31 $12,535
2010-09-30 $9,705
2010-06-30 $9,903
2010-03-31 $10,489
2009-12-31 $10,328
2009-09-30 $4,410
2009-06-30 $4,479
2009-03-31 $4,191
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $226.779B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Novartis AG (NVS) Switzerland $192.828B 14.22